Sanofi beefs up CMO game with Transgene deal

France's Sanofi ($SNY) is expanding its contract manufacturing capabilities, teaming up with Transgene to spend $13 million on a new CMO platform. Both companies are pitching in to launch the effort, and Sanofi will act as Transgene's CMO and produce clinical and commercial batches of the company's therapies, granting Transgene a 15-year preferred customer tag. Sanofi expects to get the new platform up and running later this year, and the drugmaker is open to working with other CMO clients in the future. More